<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03136822</url>
  </required_header>
  <id_info>
    <org_study_id>DERMAN</org_study_id>
    <nct_id>NCT03136822</nct_id>
  </id_info>
  <brief_title>DERMALIX Efficacy on Diabetic Foot Ulcers</brief_title>
  <acronym>DERMAN</acronym>
  <official_title>Clinical Evaluation of the Wound Dressing Impregnated With Microparticules (DERMALIX) on Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermis Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      (DERMALIX) (Patent number: PCT/TR2014/000251) is a bioactive wound dressing that was&#xD;
      developed by Ege University School of Pharmacy Department of Pharmaceutical Technology. This&#xD;
      dressing has been categorised as Class III medical device. This clinical study will be&#xD;
      conducted in patients with diabetic foot ulcers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2017</start_date>
  <completion_date type="Actual">August 1, 2018</completion_date>
  <primary_completion_date type="Actual">May 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open label, controlled, randomised, parallel arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The wound will be assessed by Pathologists who are masked for treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery of the wound 100%</measure>
    <time_frame>1 month</time_frame>
    <description>The wound will be completely recovered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recovery of the wound 80%</measure>
    <time_frame>1 month</time_frame>
    <description>The wound will be recovered by 80%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Diabetic Foot</condition>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard dressing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard dressing + Wound dressing (DERMALIX)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Dressing</intervention_name>
    <description>Standard dressing is applied for treatment of diabetic foot ulcers</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DERMALIX</intervention_name>
    <description>DERMALIX, a class III Medical Device will be applied in addition to standard dressing</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 or 2 Patients diagnosed with diabetic foot ulcers&#xD;
&#xD;
          -  Class I and II according to Wagner classification&#xD;
&#xD;
          -  No infections confirmed with culture test&#xD;
&#xD;
          -  No osteomyelitis and gangrene in the foot&#xD;
&#xD;
          -  HbA1c values â‰¤ % 7.5&#xD;
&#xD;
          -  Not active smoker&#xD;
&#xD;
          -  No planned treatment of hyperbaric oxygen&#xD;
&#xD;
          -  Patients who give consent for the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with diabetic foot ulcer of class 3,4 and 5 according to Wagner&#xD;
             classification&#xD;
&#xD;
          -  Patients who are pregnant or breast-feeding or female who are in reproductive age&#xD;
             applying no preservative method&#xD;
&#xD;
          -  Patients who have mental conditions that lead to difficulties in comprehension&#xD;
&#xD;
          -  Patients who may have compliance issues&#xD;
&#xD;
          -  Patients who have been included to another interventional study with drug or medical&#xD;
             device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sevki Cetinkalp, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ege University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ege University School of Medicine</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>April 28, 2017</study_first_submitted>
  <study_first_submitted_qc>April 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>August 2, 2018</last_update_submitted>
  <last_update_submitted_qc>August 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic Foot</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

